Market research
DXB.AU Dimerix Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 186M
- P/E ratio
- Not available
- Analyst target
- 1.895
- Dividend yield
- Not available
- Beta
- 0.33
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000DXB7
- Market cap
- 186M
- P/E ratio
- Not available
- Analyst target
- 1.895
- Dividend yield
- Not available
- Beta
- 0.33
About
About Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the DXB.AU discussion.
5 years, 5 months ago
Dimerix Limited is currently in a long term downtrend where the price is trading 13.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Dimerix Limited's total revenue sank by 33.7% to $1K since the same quarter in the previous year.
Its net income has dropped by 31.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 11.4% to $-924K since the same quarter in the previous year.
Based on the above factors, Dimerix Limited gets an overall score of 2/5.